Making a deal on ADCs

Trio Pharmaceuticals and Ajinomoto enter into development collaboration
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
SAN DIEGO & SAN FRANCISCO—This spring, Trio Pharmaceuticals Inc., a cancer therapeutics company developing novel antibody drugs (TRIObody and TRIObody Drug Conjugate, or TDC), and Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services, announced a development agreement.
 
Under this deal, they will evaluate AJICAP, a proprietary site-specific conjugation technology offered by Aji Bio-Pharma for the development of TDC candidates. The AJICAP technology will be used to conjugate a cytotoxic payload to Trio’s lead oncology candidate, with Trio evaluating functionality of the TDC.
 
TDCs are a first-in-class kind of antibody-drug conjugate (ADC) with dual functionality that utilizes targeted payload delivery to stop both tumor growth and immunosuppression. By generating a less immunosuppressive tumor microenvironment, TDC reportedly enhances activation of tumor-specific immune effector cells, further facilitating cancer cell destruction.
 
AJICAP is a site-specific conjugation technology compatible with various antibody modalities. AJICAP’s advantage is its “off-the-shelf” feature, allowing any antibody drug at any stage of development to be conjugated to drug payloads of choice without the need to modify the sequence.
 
“The AJICAP conjugation technology marks a new beginning in the ADC field, allowing generation of ADCs with site-specific conjugation without change in antibody sequence, a rate-limiting step in the development of site-specific ADCs,” said Dr. Shiva Bhowmik, CEO of Trio Pharmaceuticals. “Setting an early collaboration with Aji Bio-Pharma will ease our cGMP plans for clinical development.”

Related Topics

Published In

Volume 16 - Issue 6 | June 2020

June 2020

June 2020 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Image Alt Text	A laboratorian wearing blue gloves places a PCR sample into a real-time PCR thermocycler, the model shown is blue and white with a large digital screen.
From primer design to sample preparation, explore comprehensive strategies to optimize PCR throughput and reproducibility.
Tackling mycoplasma contamination in biotherapeutic production
DNA-based testing is emerging as a sensitive way to uncover and control a hidden threat in biomanufacturing.
Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue